A New Standard for Malignant Pleural Mesothelioma

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2016 Jan 1

PMID 26719231

Citations 5

Authors

Marjorie G Zauderer

Affiliations

Soon will be listed here.

Citing Articles

The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.

Offin M, Fitzgerald B, Zauderer M, Doroshow D J Cancer Metastasis Treat. 2024; 9.

PMID: 38895597 PMC: 11185317. DOI: 10.20517/2394-4722.2022.140.

Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.

Jiang Y, Zhang C, Chen Y, Zhao S, He Y, He J Cancer Med. 2022; 12(4):4895-4906.

PMID: 36031798 PMC: 9972025. DOI: 10.1002/cam4.5174.

The necessity of a more aggressive initial surgical treatment in patients with mesothelioma of the testicular tunica vaginalis.

Brun C, Giusiano S, Thiam K, Guinde J, Froudarakis M, Astoul P Ann Med Surg (Lond). 2019; 47:57-60.

PMID: 31692693 PMC: 6806379. DOI: 10.1016/j.amsu.2019.10.012.

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?.

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N Eur Respir Rev. 2018; 27(147).

PMID: 29540495 PMC: 9488560. DOI: 10.1183/16000617.0098-2017.

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Bibby A, Tsim S, Kanellakis N, Ball H, Talbot D, Blyth K Eur Respir Rev. 2016; 25(142):472-486.

PMID: 27903668 PMC: 9487555. DOI: 10.1183/16000617.0063-2016.

References

Stahel R, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I . Searching for targets for the systemic therapy of mesothelioma. Ann Oncol. 2015; 26(8):1649-60. DOI: 10.1093/annonc/mdv101. View

Buikhuisen W, Burgers J, Vincent A, Korse C, van Klaveren R, Schramel F . Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013; 14(6):543-51. DOI: 10.1016/S1470-2045(13)70125-6. View

Dubey S, Janne P, Krug L, Pang H, Wang X, Heinze R . A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010; 5(10):1655-61. PMC: 3823555. DOI: 10.1097/JTO.0b013e3181ec18db. View

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G . Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193(4):468-75. DOI: 10.1002/path.824. View

Jahan T, Gu L, Kratzke R, Dudek A, Otterson G, Wang X . Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2011; 76(3):393-6. PMC: 4778731. DOI: 10.1016/j.lungcan.2011.11.014. View

Ladanyi M, Zauderer M, Krug L, Ito T, McMillan R, Bott M . New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012; 18(17):4485-90. PMC: 3432735. DOI: 10.1158/1078-0432.CCR-11-2375. View

Hellmann M, Kris M, Rudin C . Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails". JAMA Oncol. 2015; 2(2):167-8. DOI: 10.1001/jamaoncol.2015.4345. View

Kindler H, Friberg G, Singh D, Locker G, Nattam S, Kozloff M . Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005; 23(31):8033-40. DOI: 10.1200/JCO.2005.01.9661. View

Ohta Y, Shridhar V, Bright R, Kalemkerian G, Du W, Carbone M . VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999; 81(1):54-61. PMC: 2374345. DOI: 10.1038/sj.bjc.6690650. View

10.

Pastan I, Hassan R . Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014; 74(11):2907-12. PMC: 4062095. DOI: 10.1158/0008-5472.CAN-14-0337. View

11.

Nowak A, Millward M, Creaney J, Francis R, Dick I, Hasani A . A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012; 7(9):1449-56. DOI: 10.1097/JTO.0b013e31825f22ee. View

12.

Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View